Status:
COMPLETED
Effects of Fimasartan on Insulin Secretion in Type 2 Diabetic Patients
Lead Sponsor:
Seoul National University Hospital
Conditions:
Diabetes Mellitus
Hypertension
Eligibility:
All Genders
20-80 years
Phase:
NA
Brief Summary
This study was designed to evaluate the effect of ARB in improving insulin secretion in patients with type 2 diabetes. The investigators also aimed to evaluate if there are potential synergisms betwee...
Detailed Description
Angiotensin II has been reported to insulin secretion in beta cells. Angiotensin II indirectly improves insulin secretion in beta cells via vasoconstriction and reduced islet blood flow. Chronic expos...
Eligibility Criteria
Inclusion
- Aged 20\~80 years
- Type 2 diabetic patients diagnosed more than 6 months ago
- HbA1c ≤8.5% at screening
- No change of OAD within the 3 months before screening
- SBP \<140 mmHg and DBP \<90 mmHg with anti-hypertensive drug at screening
- SBP ≥140 mmHg or DBP ≥80 mmHg without anti-hypertensive drug at screening
Exclusion
- Type 1 diabetic patients or active insulin treatment at screening
- Treatment with ARB or ACEi within 1 month prior to screening
- Uncontrolled hypertension with SBP \>170 mmHg or DBP \>100 mmHg
- Pregnancy or lactation
- Elevated liver enzyme (AST or ALT \> 3 times the UNL) or elevated serum Cr (≥1.5 mg/dL in men and 1.4 mg/dL in women)
Key Trial Info
Start Date :
March 1 2015
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 1 2017
Estimated Enrollment :
46 Patients enrolled
Trial Details
Trial ID
NCT02312375
Start Date
March 1 2015
End Date
March 1 2017
Last Update
April 28 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Seoul National University Hospital
Seoul, South Korea, 110-144